Marco Davila
SVP, Translational Research
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (14)
Year:
2026
Chimeric antigen receptor (CAR) T cell therapy has reshaped the therapeutic landscape for multiple myeloma (MM), yet most patients treated with BCMA-targeted CAR T cells experience disease relapse. Consequently, we sought to determine if inhibition of CD28 survival signaling could increase MM sensitivity to CAR T cell therapy. Contrary to expectations, blockade of CD28 interaction with CD80/86 accelerated tumor regrowth in preclinical MM and lymphoma CAR T therapy models. Knockout studies revealed that endogenous CD28 on 4-1BB co-stimulated CAR T cells prolonged in vivo activity, reprogrammed mitochondrial metabolism to maintain redox balance, and stimulated proliferation and release of tumor-model specific inflammatory cytokines in the tumor microenvironment. Intriguingly, transient CD28 blockade decreased levels of certain TME cytokines without significantly affecting survival of CAR T cell treated mice. Collectively, these data provide direct evidence that endogenous CD28 signaling modulates CAR T cell responses in multiple myeloma and lymphoma models.
Year:
2026
Year:
2025
Year:
2025
Severe immune effector cell-associated neurotoxicity syndrome (ICANS) occurs in about 30% of all patients with large B-cell lymphoma (LBCL) who are treated with axicabtagene ciloleucel (axi-cel). There are currently limited treatment strategies other than the standard corticosteroids, and it is essential to find additional therapies to manage severe ICANS. We conducted a retrospective study of neurologic outcomes among patients who received axi-cel for LBCL from May 2015 to February 2019. We identified patients who developed severe ICANS and were treated with glucocorticoids followed by intravenous immunoglobulin (IVIG) (n = 9) or glucocorticoids alone (n = 10). There was no statistically significant difference in the time to resolution (TTR) of severe ICANS between groups; however, patients in the IVIG had more severe grades of ICANS with a lower performance status at baseline. The cumulative steroid days were 11.2 in the IVIG arm and 13.5 in the glucocorticoids-only arm. The use of IVIG for severe ICANS after axi-cel therapy was tolerable and safe and is generally recommended in the CAR-T setting in patients with hypogammaglobinemia. The use of IVIG as a potential therapeutic agent for severe ICANS can be further explored in future prospective studies.
Year:
2025
Purpose: Sarcopenia is a hallmark of cancer cachexia. Chimeric antigen receptor (CAR) T-cell therapy is associated with an inflammatory state that may exacerbate sarcopenia. The relationship among CAR T-cell therapy, sarcopenia, and metabolism is poorly understood. Experimental Design: In 83 patients with large B-cell lymphoma, the skeletal muscle index was measured from clinical images obtained at baseline and days 30 and 90 after therapy. Serum metabolomics ( n = 57 patients) was performed in the first 4 weeks. Results: Baseline sarcopenia was present in more than half of patients and associated with shorter median overall survival than for non-sarcopenic patients (10.5 vs. 34.3 months; P = 0.006). This reduction was due to increased nonrelapse mortality with all six nonrelapse mortality events occurring in patients with baseline sarcopenia. In the first 30 days after CAR T-cell therapy, one of three patients experienced skeletal muscle loss greater than 10%. Muscle loss was associated with higher tumor burden and neurotoxicity but was not significantly associated with long-term survival. Serum metabolomics revealed an early (weeks 1–2) increase in purine metabolites, followed by a later (weeks 3–4) increase in triglyceride levels. The serum metabolite with the highest fold-increase from baseline was adipic acid, attributed to the inpatient hospital menu of jello and other tart beverages. Conclusions: Skeletal muscle loss after CAR T-cell therapy is common and is associated with fatty acid catabolism. Patients with baseline sarcopenia have poor tolerance and reduced survival. Future studies of dietary and exercise interventions may improve CAR T-cell therapy outcomes.
Year:
2025
Chimeric antigen receptor (CAR) T cell therapies have revolutionized B cell malignancy treatment, but subsets of patients with large B cell lymphoma (LBCL) experience primary resistance or relapse after CAR T cell treatment. To uncover tumor microenvironment (TME)-induced resistance mechanisms, we examined patients’ intratumoral immune infiltrates and observed that elevated levels of immunoregulatory macrophages in pre-infusion tumor biopsies are correlated with poor clinical responses. CAR T cell-produced interferon-gamma (IFN-γ) promotes the expression of inducible nitric oxide synthase (iNOS, NOS2) in immunoregulatory macrophages, impairing CAR T cell function. Mechanistically, iNOS-expressing macrophages upregulated the p53 pathway, mediating apoptosis and cell cycle arrest in CAR T cells, while downregulating the MYC pathway involved in ribosome biogenesis and protein synthesis. Furthermore, CAR T cell metabolism is compromised by depletion of glycolytic intermediates and rewiring of the TCA cycle. Pharmacological inhibition of iNOS enhances the CAR T cell treatment efficacy in B cell tumor-bearing mice. Notably, elevated levels of iNOS+CD14+ monocytes were observed in leukaphereses of patients with non-durable response to CAR T cell therapy. These findings suggest that mitigating iNOS in tumor-associated macrophages (TAMs) by blocking IFN-γ secretion from CAR T cells will improve outcomes for LBCL patients.
Year:
2025
CAR-T therapy has led to significant improvements in patient survival. However, a subset of patients experience high-grade toxicities, including cytokine release syndrome (CRS) and immune cell-associated hematologic toxicity (ICAHT). We utilized IL-2Rα knockout mice to model cytokine toxicities with elevated levels of IL6, IFNγ, and TNFα and increased M1-like macrophages. Onset of CRS was accompanied by a reduction in peripheral blood neutrophils due to disruption of bone marrow neutrophil homeostasis characterized by an increase in apoptotic neutrophils and a decrease in proliferative and mature neutrophils. Both non-tumor-bearing and Eμ-ALL tumor-bearing mice recapitulated the co-occurrence of CRS and neutropenia. IFNγ-blockade alleviated CRS and neutropenia without affecting CAR-T efficacy. Mechanistically, a Th1-Th17 imbalance was observed to drive co-occurrence of CRS and neutropenia in an IFNγ-dependent manner leading to decreased IL-17A and G-CSF, neutrophil production, and neutrophil survival. In patients, we observed an increase in the IFNγ-to-IL-17A ratio in the peripheral blood during high-grade CRS and neutropenia. We have uncovered a biological basis for ICAHT and provide support for the use of IFNγ-blockade to reduce CRS and neutropenia. Statement of Significance Despite clinical success of CAR-T therapy, patients develop toxicities such as cytokine release syndrome and neutropenia, whose co-occurrence impacts their survival and quality-of-life. We recapitulate these toxicities in mice to discover their co-occurrence is driven by Th1-Th17 imbalance following CAR-T administration, which can be prevented via IFNγ blockade.
Year:
2025
Purpose: Acute and chronic GVHD remain major causes of transplant-related morbidity and mortality (TRM) after allogeneic hematopoietic cell transplantation (alloHCT). We have shown CD83 chimeric antigen receptor (CAR) T cells prevent GVHD and kill myeloid leukemia cell lines. In this pilot study, we investigate CD83 expression on GVHD effector cells, correlate these discoveries with clinical outcomes, and evaluate critical therapeutic implications for transplant recipients. Experimental Design: CD83 expression was evaluated among circulating CD4 + T cells, B-cell subsets, T follicular helper (Tfh) cells, and monocytes from patients with/without acute or chronic GVHD ( n = 48 for each group), respectively. CD83 expression was correlated with survival, TRM, and relapse after alloHCT. Differential effects of GVHD therapies on CD83 expression was determined. Results: CD83 overexpression on CD4 + T cells correlates with reduced survival and increased TRM. Increased CD83 + B cells and Tfh cells, but not monocytes, are associated with poor posttransplant survival. CD83 CAR T eliminate autoreactive CD83 + B cells isolated from patients with chronic GVHD, without B-cell aplasia as observed with CD19 CAR T. We demonstrate robust CD83 antigen density on human acute myeloid leukemia (AML), and confirm potent antileukemic activity of CD83 CAR T in vivo , without observed myeloablation. Conclusions: CD83 is a promising diagnostic marker of GVHD and warrants further investigation as a therapeutic target of both GVHD and AML relapse after alloHCT.
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (36)
Yun Pyo Kang
Assistant Professor
Seoul National University
Xuefeng Wang
Associate Member/Professor
H Lee Moffitt Cancer Center and Research Institute
Joseph Maakaron
Assistant Professor
University of Minnesota
Brian C. Betts
Vice Chair
Roswell Park Comprehensive Cancer Center
Daniel Weisdorf
Faculty, Leader
University of Minnesota
James J. Driscoll
Assistant Director
Case Western Reserve University
Najla El Jurdi
Assistant Professor
University of Minnesota
Johannes Fahrmann
Assistant Professor
The University of Texas MD Anderson Cancer Center
Scott Olejniczak
Associate Professor of Oncology
Roswell Park Comprehensive Cancer Center
Margaret MacMillan
Faculty, Professor
University of Minnesota
Jianmin Wang
Associate Professor
Roswell Park Comprehensive Cancer Center
Jonathan Bramson
Vice Dean Research
McMaster University
Julio Chavez
Associate Professor
Moffitt Cancer Center
Hamza Hassan
Roswell Park Comprehensive Cancer Center
Christina Bachmeier
H Lee Moffitt Cancer Center and Research Institute
Hiroshi Kotani
Professor and Cairman
University of the Ryukyus
Bruce Blazar
Regents Professor
University of Minnesota
Samir M. Hanash
The University of Texas MD Anderson Cancer Center
Veronika Bachanova
Faculty, Professor
University of Minnesota
Marion Subklewe
Head of Hematology with Focus on Cellular Therapy, CAR T and ECTU & LMU - Gene Center - Head of the Laboratory of Translational Cancer Immunology
Ludwig-Maximilians-Universität München
Muhammad Junaid Tariq
Clinical Assisstant Professor
University of Florida
Connor Demorest
University of Minnesota
Martin Felices
Associate Professor
University of Minnesota
Aditi Saha
Assistant Professor
H Lee Moffitt Cancer Center and Research Institute
Jay Spiegel
Assistant Professor
University of Miami
Timothy Shaw
Assistant Member/Professor
Moffitt Cancer Center
Robert Jenq
Professor
City Of Hope National Medical Center
Michael Jain
Associate Member
H Lee Moffitt Cancer Center and Research Institute
Jeffrey S Miller
University of Minnesota System
Neeraj Y Saini
Associate Professor
The University of Texas MD Anderson Cancer Center
Anne Eaton
Faculty, Associate Professor
University of Minnesota
Marion Subklewe
LMU University Hospital
Fabiana Perna
H Lee Moffitt Cancer Center and Research Institute
Ciara Louise Freeman
Assistant Professor
H Lee Moffitt Cancer Center and Research Institute
Paulo Rodriguez
Senior Member-Professor
H Lee Moffitt Cancer Center and Research Institute
Shernan Holtan
Assistant Professor
Roswell Park Comprehensive Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.